Exclusives

Avita enters into an exclusive 5-year development and distribution agreement with Regenity Biosciences for a unique collagen-based dermal matrix. Upon 510(k) clearance expected Q424, Avita will make an initial $2.0MM payment followed by...

MiMedx announces the launch of its first xenograft product, HELIOGEN, a particulate fibrillar bovine collagen matrix for addressing complex wounds primarily in the surgical setting.

Polaroid Therapeutics announced its partnership with Speciality Fibres and Materials Ltd to test a novel wound dressing that prevents infection and aids healing. The trials aim to create a breakthrough in advanced wound care, particularly for...

MiMedx management noted that the increase in revenue was partially offset by commercial challenges due to sales of artificially high-priced skin substitute products by competitors, the uncertainty of Medicare reimbursements and sales team...

Results of a 196-patient RCT comparing the efficacy of ExcharEx for debridement of VLUs vs placebo (GV) and nonsurgical SoC (NSSOC) showed a significantly higher incidence of complete debridement at 63% compared to GV (30.2%) and NSSOC (13%),...

AOTI announces US FDA 510(k) Clearance for an extension of the indications for their NEXATM NPWT System. The amended indications, "for use in acute, extended and home care settings…," will allow the device to be marketed to additional care...

Integra announced plans to restart the manufacture of PriMatrix and SurgiMend at its new manufacturing facility in Braintree, Massachusetts in H126. IART also noted it expects Integra Skin sales to be at normalized run rates during Q424. IART...

In H224, Convatec expects to further grow sales of InnovaMatrix by pursuing other indications and by starting the launch of InnovaMatrix outside of the US. In addition, RCT’s are to be initiated for VLUs and DFUs in Q324. CTEC H124 Earnings...

BioStem Technologies initiated a 60-patient RCT to evaluate the safety and efficacy of AmnioWrap2 plus SoC vs SoC only for treatment of DFUs with primary outcome of % of wound closure over 12 weeks. Not yet recruiting; estimated study...